Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005026 | 0.92 | STS (0.42) | STSUSP30ANO1MEN1KMT2A | |
| SCHEMBL3001819 | 0.87 | REN (0.44) | STSUSP30ANO1FNTAFNTB | |
| SCHEMBL2998132 | 0.87 | STS (0.43) | STSUSP30ANO1MEN1KMT2A | |
| SCHEMBL2989962 | 0.84 | STS (0.42) | STSUSP30ANO1MEN1KMT2A | |
| SCHEMBL4597911 | 0.79 | MEN1 (0.53) | STSMEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL968749 | 0.76 | REN (0.53) | — | |
| SCHEMBL3611603 | 0.76 | REN (0.53) | — | |
| SCHEMBL968751 | 0.76 | REN (0.53) | — | |
| SCHEMBL742853 | 0.76 | STS (0.47) | STSUSP30ANO1MEN1KMT2A | |
| SCHEMBL330770 | 0.75 | PGR (0.47) | USP30MEN1KMT2ACNR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
| WO-2008156828-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190829-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | STS 1946/4885USP30 684/4885ANO1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.